Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer

dc.contributor.authorKhandelwal, Akanksha
dc.contributor.authorSharma, Uttam
dc.contributor.authorBarwal, Tushar Singh
dc.contributor.authorSeam, Rajeev Kumar
dc.contributor.authorGupta, Manish
dc.contributor.authorRana, Manjit Kaur
dc.contributor.authorVasquez, Karen M.
dc.contributor.authorJain, Aklank
dc.date.accessioned2024-01-21T10:44:35Z
dc.date.accessioned2024-08-13T13:22:21Z
dc.date.available2024-01-21T10:44:35Z
dc.date.available2024-08-13T13:22:21Z
dc.date.issued2021-03-23T00:00:00
dc.description.abstractDysregulated expression profiles of microRNAs (miRNAs) have been observed in several types of cancer, including non-small cell lung cancer (NSCLC); however, the diagnostic and prognostic potential of circulating miRNAs in NSCLC remains largely undefined. Here we found that circulating miR-320a was significantly down-regulated (~5.87-fold; p < 0.0001) in NSCLC patients (n = 80) compared to matched control plasma samples from healthy subjects (n = 80). Kaplan-Meier survival analysis revealed that NSCLC patients with lower levels of circulating miR-320a had overall poorer prognosis and survival rates compared to patients with higher levels (p < 0.0001). Moreover, the diagnostic and prognostic potential of miR-320a correlated with clinicopathological characteristics such as tumor size, tumor node metastasis (TNM) stage, and lymph node metastasis. Functionally, depletion of miR-320a in human A549 lung adenocarcinoma cells induced their metastatic potential and reduced apoptosis, which was reversed by exogenous re-expression of miR-320a mimics, indicating that miR-320a has a tumor-suppressive role in NSCLC. These results were further supported by high levels of epithelial-mesenchymal transition (EMT) marker proteins (e.g., Beta-catenin, MMP9, and E-cadherin) in lung cancer cells and tissues via immunoblot and immunohistochemistry experiments. Moreover, through bioinformatics and dual-luciferase reporter assays, we demonstrated that AKT3 was a direct target of miR-320a. In addition, AKT3-associated PI3K/AKT/mTOR protein-signaling pathways were elevated with down-regulated miR-320a levels in NSCLC. These composite data indicate that circulating miR-320a may function as a tumor-suppressor miRNA with potential as a prognostic marker for NSCLC patients. � Copyright � 2021 Khandelwal, Sharma, Barwal, Seam, Gupta, Rana, Vasquez and Jain.en_US
dc.identifier.doi10.3389/fonc.2021.645475
dc.identifier.issn2234943X
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/3797
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fonc.2021.645475/full
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.subjectcanceren_US
dc.subjectliquid biopsyen_US
dc.subjectmiR-320aen_US
dc.subjectNSCLCen_US
dc.subjectprognosisen_US
dc.titleCirculating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Canceren_US
dc.title.journalFrontiers in Oncologyen_US
dc.typeArticleen_US
dc.type.accesstypeOpen Accessen_US

Files